Mastering Modified Release: The Pellet-Based Approach
Explore how pellet-based systems can de-risk development and scale-up of robust modified-release formulations across the product lifecycle.
Aenova Group
Small Molecules: Choosing a Strategic, Scalable, and De-Risked Development Path
Early CMC decisions determine success. Learn how structured planning and enabling technologies accelerate small-molecule programs to the clinic.
Aenova Expands Fill & Finish Capacities at its Latina site
Aenova will install an additional filling and manufacturing line at the Latina, Italy, site. This expansion is an important step to meet the increasing global demand for the production of biologics.
Aenova Expands its Refrigerated Logistics for Biologics
Aenova is investing in a new cold storage infrastructure at its sterile site in Latina (Italy), offering an end-to-end supply chain solution for biologics and other pharmaceutical products.
Motivation, Innovation, and the Power of Collaboration
Leading the Way in Pharmaceutical Manufacturing by Fostering an Agile Mindset and an Inclusive Culture.
Aenova Launches Program to Accelerate Pharmaceutical Development
Aenova announces the launch of its Aenovation program. This initiative aims to accelerate the early development of pharmaceutical formulations.
The Evolution of the CDMO Industry
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Expert Statement: Neil Jones, Aenova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Kühne Holding Acquires Aenova from BC Partners
Kühne Holding has agreed to purchase Aenova Group, a pharma contract development and manufacturing organization (CDMO), from BC Partners. BC will reinvest and retain a minority stake in Aenova. The financial terms remain undisclosed.
How CDMOs Can Contribute to Pharma Supply even Better
The demand for medicines is increasing rapidly and R&D pipelines have doubled over the last decade.
Aenova Appoints Hanno Scheffczik as Managing Director of its Marburg Site
Hanno Scheffczik has been appointed as the new Managing Director of Temmler Pharma, a member of the Aenova Group. Effective Mar. 1, 2023, he succeeds Alfred Veit, who is retiring.
Vaccine Filling at the Highest Level
Recent studies show that contract manufacturers for the pharmaceutical industry, so-called CDMOs (contract development and manufacturing organizations), have so far been little involved in the production of vaccines. This is changing with the outbreak of the Covid-19 pandemic.
Aenova Expands Production of Tablets with Highly Potent Oncology Drugs
Contract manufacturer Aenova has put a third, high-performance tablet press including integrated automatic in-process control into operation at its site in Regensburg, Germany, to expand its production capacity of highly potent oncology drugs.
Facing Strong Headwinds
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
Aenova Presents New Organizational Group Structure
New structure bundles the CDMO's production areas into the business units Solids, Semi Solids & Liquids and Soft Gel Capsules.
